Industry

Industry — The Synthetic Biology / Cell-Programming Arena

Ginkgo plays in synthetic biology — engineering living cells (yeast, bacteria, mammalian) to make a specific molecule on demand: a drug, an enzyme, a crop protein, a fragrance. The industry sits at the intersection of three larger pools: pharma R&D outsourcing, life-sciences tools and automation, and government biodefense funding. What is new is the attempt to industrialize biology the way semiconductors industrialized silicon: high-throughput lab automation ("foundries"), proprietary DNA-sequence libraries, and ML models trained on experimental data.

The mental map for the rest of this report: a small group of well-funded platform companies are trying to convince pharma, ag and industrial customers to outsource biological R&D to them — and those customers' own internal labs are the dominant competing alternative.

1. Industry in One Page

The industry sells outsourced biological R&D as a service, priced as fee-for-service work (like a CRO) or as multi-year programs with royalties and milestones tied to the customer's product success. Customers are pharma, agriculture, industrial-biotech and government. Profits exist when a platform's reusable assets (automation, ML models, validated host cells, sequence libraries) let it run more experiments per dollar than a customer's in-house lab — but to date the public synbio cohort has been pre-profit and pre-cash-flow, funded by IPO proceeds raised in 2020–2021. The cycle is driven by biotech venture funding, pharma R&D budgets, and government biodefense appropriations — all three turned down sharply in 2022–2024 and revenue contracted across the cohort. The platform companies' largest competitor is not each other — it is the customer's own internal R&D team choosing to keep work in-house.

Takeaway: Ginkgo sits in layers 2 and 3 (cell-programming platform and automation tools), competes against layer 4 (CROs) on the tools side, and was — until its Q1 2026 divestiture announcement — also in layer 6 (biosecurity).

2. How This Industry Makes Money

Synbio platforms monetize biological R&D in two layers, and the mix matters more than the headline revenue number.

The profit-pool stack is unusual: nearly all near-term gross profit comes from upfront service fees and tools, but nearly all long-term equity value is supposed to come from the downstream royalty stream — which is option-like (you get paid only if a customer's drug or product reaches market). The cost stack has three big buckets:

Bargaining power sits firmly with the customer. Pharma R&D departments are sophisticated buyers with multiple alternatives (in-house, CRO, AI-bio startup, several synbio platforms) and they negotiate hard on royalty/milestone terms. Ginkgo's 2024 commercial-terms change — removing downstream value share from certain program types — was an admission that customers were unwilling to pay full royalty rates and that platforms need shorter, cleaner revenue.

3. Demand, Supply, and the Cycle

Synthetic biology is cyclical along three independent axes, and 2022–2025 was a synchronized downturn on all three.

To make the COVID-era distortion concrete: Ginkgo's biosecurity segment generated $334M of revenue in FY2022 (peak pandemic services) and just $37M in FY2025, a 89% decline. That single segment swing accounts for most of the company's revenue collapse from $478M (FY2022) to $170M (FY2025).

The cell-engineering side has its own cycle: revenue per program peaked in FY2020–2021 and has been declining since as customers negotiate harder, programs get smaller, and Ginkgo unbundles services into shorter Datapoints engagements.

4. Competitive Structure

The industry is fragmented at the platform layer and oligopolistic at the tools/CRO layer. Ginkgo's own 10-K identifies four competitor archetypes, and they have very different economics:

The listed-cohort competition is small in dollar terms but large in narrative. Five public peers cluster between roughly $260M and $3.5B of market cap and all run negative operating margins:

What the chart says: Twist sits at the most mature corner (tools-like scale, ~50% GM); AbCellera and Codexis have very high stated gross margins because their COGS lines are essentially scientist-hours rolled into operating expense, not COGS. Recursion sits at low GM because most of its "revenue" is a strategic collaboration payment with high pass-through costs. Ginkgo lands mid-pack on margin but with disproportionately large net losses relative to revenue — a sign that the platform is still oversized for its current revenue base.

5. Regulation, Technology, and Rules of the Game

Synthetic biology is regulated at the product level, not the platform level — Ginkgo itself does not need an FDA license to operate, but every customer who turns a Ginkgo-engineered cell into a drug, food, crop input, or cosmetic does. That makes regulatory cycles a demand driver, not a cost driver, and it pushes the platform's economics toward "picks-and-shovels" exposure across many regulated end markets.

On the technology side, three shifts have changed economics in the last 24 months: (1) generative protein and DNA-sequence models have substantially reduced the experimental rounds needed for protein-engineering campaigns; (2) lab automation has crossed a usability threshold — "autonomous lab" workflows that needed a PhD-level operator in 2020 now run with limited supervision; (3) DNA synthesis costs have fallen another order of magnitude, eroding the moat of legacy DNA-tools vendors and pushing differentiation up the stack toward proprietary datasets and screening assays.

6. The Metrics Professionals Watch

For a pre-profit synbio platform, the usual GAAP scorecard is misleading — net income is a function of stock-based compensation and impairments more than business momentum. The metrics that actually move investor judgment are below.

The chart captures the central tension: cumulative program count keeps growing (the royalty option pool builds), but new programs per year peaked in FY2023 and fell roughly 33% in FY2024, indicating that the platform's top-of-funnel slowed before management announced the 2024 commercial-terms changes.

7. Where Ginkgo Bioworks Holdings Inc. Fits

Ginkgo is the largest horizontal cell-programming platform in the public market — broader by end-market breadth than any single vertical specialist, but smaller by revenue than the tools-oriented public peers (Twist, Schrödinger). It is best thought of as a biology-focused R&D-services platform attempting to become a tools/automation business, while sitting on a long-tail royalty option book from prior multi-year programs.

8. What to Watch First

Five-to-seven observable signals that will tell you whether the synbio industry backdrop is improving or deteriorating for Ginkgo, ordered by how quickly each one shows up.

Bottom line: Ginkgo plays in a structurally growing market with a real technology edge, but it competes for a customer dollar that has cheaper alternatives in CRO and in-house R&D, and it has burned cash through a synchronized downturn in all three of its demand engines.